Keryx Biopharmaceuticals, Inc. Announces Pricing of $110 Million Public Offering of Common Stock

NEW YORK, Jan. 21, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals,
Inc. (Nasdaq:KERX) today announced the pricing of an underwritten
public offering of common stock consisting of 9,166,667 shares at
$12.00 per share, for gross proceeds of $110 million. In connection
with this offering, Keryx granted to the underwriters a 30-day option
to purchase additional shares of common stock, equal to up to 15% of
the number of shares of common stock sold in the offering. Keryx
intends to use the net proceeds from the sale of its common stock to
fund the ongoing commercialization and development of Auryxia(TM)
(ferric citrate) in the US, pre-commercial activities in Europe, to
potentially in-license, acquire and develop additional drug candidates,
and other general corporate purposes.

J.P. Morgan Securities LLC is acting as sole book-running manager in
the offering. The lead manager for the offering is Cowen and Company,
LLC. Co-managers for the offering are Oppenheimer & Co. Inc.; JMP
Securities LLC; Stifel, Nicolaus & Company, Incorporated; Mizuho
Securities USA; Roth Capital Partners, LLC; Brean Capital, LLC;
Ladenburg Thalmann & Co. Inc.; Maxim Group LLC; H.C. Wainwright & Co.;
and MLV and Company LLC. Trout Capital LLC is acting as an advisor to
the company.

The securities described above are being offered by Keryx pursuant to a
Form S-3 shelf registration statement (including a base prospectus)
previously filed with the Securities and Exchange Commission ("SEC").
Before you invest, you should read the prospectus in the registration
statement and related prospectus supplement that Keryx has filed with
the SEC for more complete information about Keryx and this offering.
The prospectus supplement is available for free by visiting EDGAR on
the SEC's website located at www.sec.gov. Copies of the prospectus
supplement and accompanying prospectus may also be obtained from the
offices of J.P. Morgan Securities LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, New York 11717
(telephone: 866-803-9204).

This news release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor will there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, headquartered in New York, is focused on
bringing innovative therapies to market for patients with renal
disease. The Company launched its first FDA-approved product, Auryxia,
in the United States in December 2014. In January 2014, ferric citrate
was approved for the treatment of patients with all stages of CKD in
Japan, where it is being marketed as Riona(R) by Keryx's Japanese
partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. For more
information about Keryx, please visit www.keryx.com.

Cautionary Statement

Some of the statements included in this press release, particularly
those regarding the commercialization and subsequent clinical
development of Auryxia, may be forward-looking statements that involve
a number of risks and uncertainties. For those statements, we claim the
protection of the safe harbor for forward-looking statements contained
in the Private Securities Litigation Reform Act of 1995. Among the
factors that could cause our actual results to differ materially are
the following: whether Auryxia will be successfully launched and
marketed in the U.S.; whether Riona(R) will be successfully marketed by
our Japanese partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co.,
Ltd; the risk that the EMA may not concur with our interpretation of
our registration studies in ESRD and non-dialysis dependent chronic
kidney disease, supportive data, conduct of the studies, or any other
part of our MAA submission and could ultimately deny approval of the
MAA; the risk that we may not be successful in the development of
ferric citrate for the treatment of iron deficiency anemia in
non-dialysis chronic kidney disease patients; and other risk factors
identified from time to time in our reports filed with the Securities
and Exchange Commission. Any forward-looking statements set forth in
this press release speak only as of the date of this press release. We
do not undertake to update any of these forward-looking statements to
reflect events or circumstances that occur after the date hereof. This
press release and prior releases are available at http://www.keryx.com.
The information found on our website is not incorporated by reference
into this press release and is included for reference purposes only.


CONTACT: KERYX CONTACT:

Amy Sullivan, Vice President - Corporate Development and
Public Affairs
Keryx Biopharmaceuticals, Inc.
Tel: 617.466.3447
E-mail: [email protected]

Suggested Articles

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…

Biogen plans to test its SMA drug Spinraza at a higher-than-approved dose as Novartis' rival gene therapy Zolgensma picks up traction.